CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer.

Abstract

Simple SummaryIt is necessary to explore a reliable predictive biomarker for immunotherapeutic strategies in bladder cancer. As an important member of tumor-infiltrating immune cells, cytotoxic T cells are the ultimate effectors of cancer rejection because of their specificity against cancer cells and cytolytic capabilities. Based on RNA expression data, we found that among T cytotoxic pathway-related genes, CD8A is a novel protective gene in bladder cancer. CD8A expression is highly associated with tumor microenvironment characteristics and tumor mutation burden, which partially explain CD8A as a prognostic and immunotherapy predictive biomarker in bladder cancer. In addition, we performed the radiogenomics in bladder cancer based on the RNA-sequence data and MRI-based radiomics features in our center. In this way, an MRI-based radiomics signature has the potential to preoperatively predict the expression of CD8A, thereby contributing to the preoperative prediction of prognosis and immunotherapeutic susceptibility in bladder cancer.As an important member of T cytotoxic pathway-related genes, CD8a molecule (CD8A) may be a useful biomarker of immunotherapeutic response and immune cell infiltration. We aimed to investigate the clinical predictive value of CD8A in prognosis and tumor microenvironment (TME) and preoperatively predict the expression of CD8A using radiogenomics in bladder cancer (BCa). Among 12 T cytotoxic pathway-related genes, CD8A was a novel protective gene and had the highest correlations with T cells and Macrophages M1 in BCa. In advanced cancer patients treated with immunotherapy, low CD8A expression was associated with immunotherapeutic failure and poor survival outcomes. CD8A expression was highly related to tumor mutation burden, critical immune checkpoint genes and several types of tumor-infiltrating immune cells, predicting effective response to immunotherapy. The preoperative MRI radiomics features and RNA-sequence data of 111 BCa samples were used to develop a radiomics signature that achieved good performance in the prediction of CD8A expression in both the training (area under curve (AUC): 0.857) and validation sets (AUC: 0.844). CD8A is a novel indicator for predicting the prognosis and immunotherapeutic response in BCa. A radiomics signature has the potential to preoperatively predict the expression of CD8A in BCa patients.